CSPC Innovation pursues Hong Kong IPO as parent profits shrink
The producer of food additives and pharmaceutical ingredients is aiming to raise fresh capital to support its drive to become a developer of innovative drugs Key takeaways: R&D costs have…
A healthy return: drug spin-off nets Keymed up to $320 million
The Chinese biotech set up a separate “NewCo” company for its autoimmune drug, beating the likely proceeds from a conventional out-licensing deal Key Takeaways: International drug rights were transferred to…
RemeGen scores out-licensing triple play with AbbVie deal
The agreement marks the drug maker’s third such transaction since last year, setting records for both its largest upfront payment and highest total deal value Key Takeaways: PD-1/VEGF bispecific antibodies…
InnoCare licensing deal flops due to lack of upfront cash
The Chinese biotech agreed to sell some of the rights to its flagship drug for a sum that could exceed $2 billion but investors were unhappy with the fine print…
Precision cancer drugs show promise for Kelun-Biotech
The company reported rising sales of its signature cancer drug and could get national insurance coverage for other key products, potentially boosting full-year earnings Key Takeaways: Topline revenue actually fell…
RemeGen’s $4.2 billion licensing deal falls flat with investors
The biopharma firm had fanned excitement over a rights deal for its autoimmune drug but the eventual terms, with just a small portion of upfront cash, left the market disappointed…
No respite for RemeGen as problems and losses pile up
The developer of innovative drugs has sustained a series of blows to its finances, corporate partnerships, management team and star product, leaving investors jittery Key Takeaways: Despite rising revenue, RemeGen…
Recent Articles
RemeGen scores out-licensing triple play with AbbVie deal
9995.HK
688331.SHG
InnoCare licensing deal flops due to lack of upfront cash
9969.HK
688428.SHG
RemeGen’s $4.2 billion licensing deal falls flat with investors
9995.HK
688331.SHG
No respite for RemeGen as problems and losses pile up
9995.HK
688331.SHG
RELATED ARTICLES
-
Big deal, bigger doubts: CSPC slides after $18.5 billion pact
-
InSilico lands drug discovery deal after Hong Kong IPO
3696.HK
- Mega licensing deal lifts 3SBio profits but core sales slip
- Cosmoplat asserts independence from parent Haier with Hong Kong IPO
- Jacobio Pharma poised to turn a profit from precision cancer drugs
